Submission to FDA of cases of suspected vancomycin-resistant Enterococcus faecium resistant to linezolid will likely show a lower frequency of documented cases of resistance than reported in an April 14 article in The Lancet. In the 45-patient study, one patient (2.2%) had documented resistance to linezolid in VRE. Pharmacia's reports to FDA will include patients from clinical trials and compassionate-use programs. The company intends to file for the treatment of infections due to penicillin-resistant Streptococcus pneumoniae at the end of 2001 or early 2002
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth